Cite
HARVARD Citation
Postel-Vinay, S. et al. (2023). First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). Journal for immunotherapy of cancer. 11 (3), p. . [Online].